Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation, Biologic therapy.

University of California, San Francisco, San Francisco, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:San Francisco, CA
Treatments:Chemotherapy, Radiation, Biologic therapyHospital:University of California, San Francisco
Drugs:Journal:Link
Date:Sep 2011

Description:

Patients:
This phase II study involved 66 patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma. The median patient age was 57 years. The breakdown of patient gender was not provided.

Treatment:
Patients were treated with radiation therapy, the chemotherapy agent temozolomide, and the biologic agent enzastaurin (a serine/threonine kinase inhibitor that interferes with cancer cell growth).

Toxicities:
The most severe adverse effect reported was of grade 4. Grade 3/4 toxicities included lymphopenia and decreased platelet count. Pneumonia and urinary tract infection was also reported.

Results:
The median progression-free survival was 8.3 months and the median overall survival was 17.0 months.

Support:
This study was supported by Eli Lilly, makers of enzastaurin.

Correspondence: Dr. Nicholas Butowski; email: [email protected]



Back